Following the encouraging publications from the last couple of years, we start seeing more and more patients being treated with Aclasta® (zoledronic acid 5 mg) for osteoporosis. Since this yearly infusion increases bone mineral density (BMD) at the lumbar spine significantly ( better than oral risedronate 5mg taken daily ) and has the advantage of improved compliance, it is used as a replacement therapy for the “per os bisphosphonates”.Recently I started having patients taking this yearly infusion and needing periodontal surgery, implants or extractions. Since there is no reports regarding complications or treating adjustments for these kind of patients- I was wondering whether any one of you can share his thoughts and/or experience ??Zoledronic acid, the active ingredient of Aclasta, is also available under the trade-name Zometa® (zoledronic acid 4mg) for use in oncology indications, and we all know the complications related to this IV intake, especially regarding osteonecrosis of the jaws.
You need to be a member of WebDental, LLC to add comments!
Replies